Pro Share Advisors LLC Recursion Pharmaceuticals, Inc. Transaction History

Pro Share Advisors LLC

$36.7 Billion
Q1 2024

A detailed history of Pro Share Advisors LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 40,949 shares of RXRX stock, worth $300,975. This represents 0.0% of its overall portfolio holdings.

Number of Shares

40,949

Previous 35,898 14.07%

Holding current value

$300,975

Previous $353,000 15.58%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$9.13 - $15.52 $46,115 - $78,391	5,051 Added 14.07%	40,949 $408,000
Q4 2023 Feb 14, 2024	BUY	$5.09 - $10.79 $24,579 - $52,104	4,829 Added 15.54%	35,898 $353,000
Q3 2023 Nov 13, 2023	BUY	$6.59 - $15.86 $9,041 - $21,759	1,372 Added 4.62%	31,069 $237,000
Q2 2023 Aug 10, 2023	BUY	$4.56 - $9.94 $4,081 - $8,896	895 Added 3.11%	29,697 $221,000
Q1 2023 May 11, 2023	SELL	$6.42 - $9.64 $24,453 - $36,718	-3,809 Reduced 11.68%	28,802 $192,000

Q4 2022 Feb 02, 2023	BUY	$7.16 - $12.7 $26,542 - $47,078	3,707 Added 12.83%	32,611 $251,000
Q3 2022 Nov 04, 2022	BUY	$7.83 - $13.6 $7,469 - $12,974	954 Added 3.41%	28,904 $308,000
Q2 2022 Aug 01, 2022	SELL	$5.04 - $9.26 $51,191 - $94,053	-10,157 Reduced 26.65%	27,950 $227,000
Q1 2022 May 10, 2022	SELL	$6.16 - $18.03 $58,778 - $172,042	-9,542 Reduced 20.03%	38,107 $272,000
Q4 2021 Feb 08, 2022	BUY	$16.14 - $21.86 $769,054 - $1.04 Million	47,649 New	47,649 $816,000
Q3 2021 Nov 12, 2021	SELL	$19.03 - $41.33 $104,322 - $226,571	-5,482 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$18.0 - $37.42 $98,676 - $205,136	5,482 New	5,482 $200,000

Others Institutions Holding RXRX

# of Institutions

260

Shares Held

192M

Call Options Held

787K

Put Options Held

1.52M

View Full List

About RECURSION PHARMACEUTICALS, INC.

Ticker RXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 180,480,000
Market Cap $1.33B
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...

More about RXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Account

Pro Share Advisors LLC Recursion Pharmaceuticals, Inc. Transaction History